Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.
OBJECTIVE
Serum levels of angiogenic cytokines decrease after radiotherapy in patients with cancer, and this may be relevant for treatment response and progression-free survival. Herein, we set out to determine whether circulating fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and platelet-derived growth factor-beta (PDGF-beta) decrease after radiotherapy in patients with non-Hodgkin lymphomas (NHLs) and if so, whether their decrease correlates with age, tumour histotype and stage, and radiation dose.


METHODS
The serum levels of FGF-2, VEGF, HGF and PDGF-beta were evaluated before and after radiotherapy by an enzyme-linked immunosorbent assay (ELISA). These levels were correlated both reciprocally and with age, histotype, stage and radiation dose.


RESULTS
After radiotherapy, FGF-2, VEGF and PDGF-beta, but not HGF, significantly decreased in relation to the radiation dose and response. No correlation was established between cytokine levels, except for VEGF and PDGF-beta, which decreased in parallel. Haemoglobin levels did not decrease after radiotherapy, while FGF-2, VEGF, HGF and PDGF-beta levels did not correlate with age, NHL stage and histotype.


CONCLUSIONS
Soluble FGF-2, VEGF and PDGF-beta levels decline after radiotherapy in NHLs, and may have predictive significance for response to treatment and recurrence.
Ria
Roberto
R
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, University of Bari Medical School, Policlinico, Piazza Giulio Cesare 11, Bari, Italy. ria@dimo.uniba.it
Cirulli
Teresa
T
Giannini
Teresa
T
Bambace
Santa
S
Serio
Gabriella
G
Portaluri
Maurizio
M
Ribatti
Domenico
D
Vacca
Angelo
A
Dammacco
Franco
F
D000328:Adult; D000368:Aged; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic
D016207:Cytokines
Nat Med. 2000 Apr;6(4):389-95
10742145
Nat Med. 1999 Dec;5(12):1359-64
10581076
Eur Cytokine Netw. 2003 Jan-Mar;14(1):40-51
12799213
J Clin Oncol. 2007 Sep 10;25(26):4033-42
17827451
Cancer Res. 2007 Oct 1;67(19):8980-4
17908997
Semin Oncol. 2001 Dec;28(6):536-42
11740806
Hormones (Athens). 2006 Apr-Jun;5(2):137-46
16807226
Head Neck. 2000 Oct;22(7):666-73
11002321
Int J Oncol. 2008 Jan;32(1):41-8
18097541
Radiother Oncol. 2003 Jan;66(1):1-9
12559515
J Clin Oncol. 2001 Feb 15;19(4):1207-25
11181687
Int J Cancer. 2001 Dec 1;94(5):690-8
11745464
Int J Cancer. 2002 Sep 1;101(1):86-94
12209593
Cancer Lett. 2002 May 28;179(2):197-203
11888674
Breast Cancer Res. 2003;5(2):83-8
12631386
Br J Haematol. 2001 Dec;115(3):514-21
11736931
Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67
17828470
Oncogene. 2007 Nov 29;26(54):7508-16
17563752
Nat Med. 2001 May;7(5):575-83
11329059
Am J Physiol Cell Physiol. 2002 May;282(5):C947-70
11940508
Blood. 2002 Nov 1;100(9):3344-51
12384436
Cancer Lett. 2004 Dec 8;216(1):103-7
15500953